vTV Therapeutics' Sickle Cell Candidate HPPD Receives FDA Orphan Drug Designation
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to vTV Therapeutics’ investigational oral therapy, HPPD, for the treatment of sickle cell disease. This first-in-class Nrf2/Bach1 modulator showed promising preclinical results by increasing fetal hemoglobin levels while reducing oxidative stress and red blood cell sickling. The company highlighted that in these studies, the increase in fetal hemoglobin was both time- and dose-dependent, with effects comparable to or better than hydroxyurea, a standard treatment for the condition. This regulatory milestone could provide vTV Therapeutics with incentives such as tax credits, market exclusivity, and assistance from the FDA during drug development. The designation is expected to support further clinical trials of HPPD and may enhance investor confidence in the company’s pipeline.
Tickers: $VTVT